YX-112, a novel celastrol-derived PROTAC, inhibits the development of triple-negative breast cancer by targeting the degradation of multiple proteins
This study provides new insights into the derivation of celastrol and its molecular mechanisms of action.
Authors
- Qiang Zhao (ORCID: https://orcid.org/0000-0003-3448-8756)
- Li-Hua Li (ORCID: https://orcid.org/0000-0003-2535-1758)
- Wen‐Shan Liu (ORCID: https://orcid.org/0000-0001-9721-6921)
- Yongxue Gu
- Wenbin Wang (ORCID: https://orcid.org/0000-0001-7287-2770)
- Mengmeng Yang
- Ying Ma (ORCID: https://orcid.org/0000-0002-6818-8578)
Institutions
- Weifang Medical University (CN)
- Second Hospital of Shandong University (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-04-15
- DOI
- https://doi.org/10.3389/fphar.2025.1571135
- Citations
- 3
- Primary Topic
- Ubiquitin and proteasome pathways
- Type
- article
- Field-Weighted Citation Impact
- 2.42
Funders
- Natural Science Foundation of Shandong Province